Patients with atrial fibrillation enrolled in the mAFA-II trial (n=1793).
Dynamic risk monitoring on anticoagulant and bleeding events using the HAS-BLED score at four timepoints (n=1077).
Usual care (n=1136).
Comparing baseline and 12 months, the proportion of atrial fibrillation patients with HAS-BLED >/=3 decreased (11.8% vs. 8.5%), with changes in use of concomitant NSAIDs/antiplatelets, renal dysfunction, and labile international normalized ratio contributing to the decreased proportions of patients with HAS-BLED >/=3. Among 1077 (60%) patients who had four bleeding risk assessments, incident bleeding events decreased significantly from Days 1-30, to Days 181-365 (1.2% to 0.2%, respectively). Total OAC usage increased from 63.4% to 70.2%. Compared to atrial fibrillation patients receiving usual care (n=1136), bleeding events were significantly lower in atrial fibrillation patients with dynamic monitoring of their bleeding risk (mAFA vs usual care, 2.1%, 4.3%).